Search results
Author(s):
Sahil Parikh
Added:
1 month ago
TCT 2025 - Three-year findings from LIFE-BTK show the Esprit™ BTK scaffold is a durable and effective treatment option for patients with CLTI.Dr Sahil Parikh (Columbia University Vagelos College of Physicians & Surgeons, New York, US) joins us to share the three-year findings from LIFE-BTK (NCT04227899). The randomized controlled trial aimed to evaluate the safety and efficacy of the Esprit™ BTK…
View more
Author(s):
Roxana Mehran
Added:
1 year ago
EuroPCR 24 - Dr Roxana Mehran (Mount Sinai Hospital, US) outlines the findings of the ABILITY Global Diabetes study onsite at EuroPCR 2024.The ABILITY study (NCT04236609) aimed to evaluate the efficacy and safety of the Abluminus DES+ Sirolimus Eluting Stent System (SES) as compared to the XIENCE Everolimus Eluting Coronary Stent System in diabetic patients eligible for percutaneous coronary…
View more
Author(s):
David Power
Added:
10 months ago
Outcomes investigating the Absorb bioresorbable vascular scaffold (BVS) in patients undergoing percutaneous coronary intervention showed more adverse ischaemic events through 5 years compared with cobalt-chromium everolimus-eluting stents. However, the period of excess risk ended at 3 years.In this short interview, Dr David Power (Mount Sinai Hospital, New York, US) discusses the final report…
View more
Daniel JFM Thuijs
Research Area(s) / Expertise:
Author
Author(s):
Byeong-Keuk Kim
Added:
6 months ago
EuroPCR 25 - Subgroup analysis outcomes from OCCUPI show optical coherence tomography-guided percutaneous coronary intervention (PCI) is an effective intravascular imaging technique for complex lesions, having successfully met its composite primary outcome measure.We are joined by Dr Byeong-Keuk Kim (Yonsei University College of Medicine, Seoul, KR) to discuss subgroup analysis findings from the…
View more
Author(s):
Andreas Torp Kristensen
,
Pascal Faltermeier
,
Caroline Barkholt Kamp
,
et al
Added:
3 weeks ago
Added:
2 years ago
Source:
AHA
AUTHOR: Jordan RanceThe American Heart Association has announced eight late-breaking science sessions to be presented in Philadelphia from November 10th to November 13th. AHA is focussed on innovation in cardiovascular disease for scientists, clinicians, researchers and other healthcare professionals.Among the event’s highlights are eight late-breaking trial sessions, as listed below.Watch our…
View more
Author(s):
Nitin Chandramohan
,
Jonathan Hinton
,
Peter O’Kane
,
et al
Added:
1 year ago
Author(s):
Khaled A Shams
,
Hossameldin Hussein
,
Soha Romeih
,
et al
Added:
1 year ago
Author(s):
Duy Cao Phuong Le
,
Hoa The Bui
,
Quan Duy Vo
Added:
1 year ago